Mechanisms of Small Molecule Inhibitors Targeting Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".
Deadline for manuscript submissions: closed (30 January 2024) | Viewed by 534
Special Issue Editor
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thyroid cancer (TC) is a highly diffuse endocrine tumor, with a rising incidence in the last 20 years. Besides traditional treatment strategies, a better understanding of the genomic landscape of TC could help clinicians to develop more tailored therapy for patients.
Tyrosine kinase receptors are involved in cancer cell proliferation and angiogenesis. The antiangiogenic multi-targeted kinase inhibitors sorafenib, lenvatinib, and cabozantinib have been approved to treat aggressive radioactive iodine (RAI)-resistant papillary TC or follicular TC. Other compounds have been introduced for TC patients that harbor specific mutations. For example, selpercatinib and pralsetinib inhibit mutant RET in medullary TC, and block RET fusion protein-mediated signaling in papillary TC; entrectinib and larotrectinib can be used in patients with progressive RAI-resistant TC harboring TRK fusion proteins; FDA authorized the association of dabrafenib (BRAFV600E inhibitor) and trametinib (MEK inhibitor) in BRAFV600E-mutated ATC.
Additional studies are needed to identify the potential effective targeted therapies for aggressive TCs, according to their molecular characterization.
Dr. Silvia Martina Ferrari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
